ETBX 011

Drug Profile

ETBX 011

Alternative Names: Ad5 [E1-, E2B-]-CEA(6D); AD5 CEA vaccine; Ad5[E1-,E2b-]-CEA vaccine; CEA-targeted vaccine - Etubics; ETBX-011

Latest Information Update: 29 Sep 2015

Price : $50

At a glance

  • Originator Etubics Corporation
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 27 Apr 2017 NantCell plans a phase I/II trial for Solid tumours (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) (NCT03127098)
  • 19 Apr 2017 NantCell plans the phase Ib/II QUILT-3.039 trial for Pancreatic cancer (Combination therapy, Second-line therapy or greater) (NCT03136406)
  • 29 Sep 2015 Clinical development is ongoing in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top